Entero Therapeutics (NASDAQ:ENTO) Shares Down 5.9% – Time to Sell?

Shares of Entero Therapeutics, Inc. (NASDAQ:ENTO) were down 5.9% during trading on Thursday . The company traded as low as $0.43 and last traded at $0.44. Approximately 1,049,335 shares changed hands during mid-day trading, an increase of 43% from the average daily volume of 731,589 shares. The stock had previously closed at $0.46.

Entero Therapeutics Price Performance

The firm has a fifty day moving average of $0.43 and a 200 day moving average of $0.50.

Entero Therapeutics (NASDAQ:ENTO) last released its earnings results on Thursday, May 15th. The company reported ($0.21) earnings per share for the quarter.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.